Do analysts rate MDRX or HTFL?

Heartflow has a consensus price target of $36.57, suggesting a potential upside of 44.95%. Given Heartflow's stronger consensus rating and higher probable upside, analysts clearly believe Heartflow is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Heartflow 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82

Which has better valuation & earnings, MDRX or HTFL?

Veradigm has higher revenue and earnings than Heartflow. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.38 N/A N/A N/A Heartflow $176.03M 12.36 -$116.79M -$3.11 N/A

Is MDRX or HTFL more profitable?

Veradigm has a net margin of 0.00% compared to Heartflow's net margin of -58.42%. Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A Heartflow -58.42% N/A -20.02%

Do analysts prefer CERT or MDRX?

Certara presently has a consensus target price of $8.85, indicating a potential upside of 9.26%. Given Certara's stronger consensus rating and higher probable upside, equities analysts plainly believe Certara is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Certara 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.46 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, CERT or MDRX?

Veradigm has higher revenue and earnings than Certara. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Certara $418.84M 3.01 -$1.60M -$0.10 N/A Veradigm $1.53B 0.38 N/A N/A N/A

Do analysts recommend TDOC or MDRX?

Teladoc Health presently has a consensus price target of $7.50, indicating a potential upside of 11.74%. Given Teladoc Health's stronger consensus rating and higher possible upside, research analysts plainly believe Teladoc Health is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teladoc Health 1 Sell rating(s) 10 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.25 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, TDOC or MDRX?

Veradigm has lower revenue, but higher earnings than Teladoc Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teladoc Health $2.53B 0.48 -$200.32M -$0.99 N/A Veradigm $1.53B 0.38 N/A N/A N/A

Do analysts recommend MDRX or SDGR?

Schrodinger has a consensus target price of $20.25, suggesting a potential upside of 33.75%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts plainly believe Schrodinger is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Schrodinger 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher earnings & valuation, MDRX or SDGR?

Veradigm has higher revenue and earnings than Schrodinger. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.38 N/A N/A N/A Schrodinger $255.87M 4.37 -$103.26M -$1.41 N/A

Do analysts rate GDRX or MDRX?

GoodRx presently has a consensus price target of $3.81, suggesting a potential upside of 24.19%. Given GoodRx's stronger consensus rating and higher probable upside, research analysts clearly believe GoodRx is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GoodRx 3 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.13 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, GDRX or MDRX?

GoodRx has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.32 $30.44M $0.06 51.17 Veradigm $1.53B 0.38 N/A N/A N/A

Is GDRX or MDRX more profitable?

GoodRx has a net margin of 2.61% compared to Veradigm's net margin of 0.00%. GoodRx's return on equity of 7.90% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.61% 7.90% 3.23% Veradigm N/A N/A N/A

Veradigm (MDRX) Competitors

$4.80 -0.20 (-4.00%)

As of 07/31/2026 03:59 PM Eastern

Compare

MDRX vs. HTFL, CERT, TDOC, SDGR, and GDRX

Should you buy Veradigm stock or one of its competitors? MarketBeat compares Veradigm with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veradigm include Heartflow (HTFL), Certara (CERT), Teladoc Health (TDOC), Schrodinger (SDGR), and GoodRx (GDRX). These companies are all part of the "healthcare technology" industry.

How does Veradigm compare to Heartflow?

Veradigm (NASDAQ:MDRX) and Heartflow (NASDAQ:HTFL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, Heartflow had 5 more articles in the media than Veradigm. MarketBeat recorded 5 mentions for Heartflow and 0 mentions for Veradigm. Heartflow's average media sentiment score of 1.03 beat Veradigm's score of 0.00 indicating that Heartflow is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Neutral
Heartflow	Positive

Heartflow has a consensus price target of $36.57, suggesting a potential upside of 44.95%. Given Heartflow's stronger consensus rating and higher probable upside, analysts clearly believe Heartflow is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Veradigm has a net margin of 0.00% compared to Heartflow's net margin of -58.42%.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Heartflow	-58.42%	N/A	-20.02%

Veradigm has higher revenue and earnings than Heartflow.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.38	N/A	N/A	N/A
Heartflow	$176.03M	12.36	-$116.79M	-$3.11	N/A

Summary

Heartflow beats Veradigm on 7 of the 11 factors compared between the two stocks.

How does Veradigm compare to Certara?

Certara (NASDAQ:CERT) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Veradigm has higher revenue and earnings than Certara.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$418.84M	3.01	-$1.60M	-$0.10	N/A
Veradigm	$1.53B	0.38	N/A	N/A	N/A

Certara has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

74.0% of Certara shares are owned by institutional investors. 1.1% of Certara shares are owned by company insiders. Comparatively, 2.3% of Veradigm shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Certara had 1 more articles in the media than Veradigm. MarketBeat recorded 1 mentions for Certara and 0 mentions for Veradigm. Certara's average media sentiment score of 0.00 equaled Veradigm'saverage media sentiment score.

Company	Overall Sentiment
Certara	Neutral
Veradigm	Neutral

Veradigm has a net margin of 0.00% compared to Certara's net margin of -3.60%. Certara's return on equity of 3.52% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Certara	-3.60%	3.52%	2.42%
Veradigm	N/A	N/A	N/A

Certara presently has a consensus target price of $8.85, indicating a potential upside of 9.26%. Given Certara's stronger consensus rating and higher probable upside, equities analysts plainly believe Certara is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.46
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Certara beats Veradigm on 10 of the 14 factors compared between the two stocks.

How does Veradigm compare to Teladoc Health?

Teladoc Health (NYSE:TDOC) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Teladoc Health had 43 more articles in the media than Veradigm. MarketBeat recorded 43 mentions for Teladoc Health and 0 mentions for Veradigm. Teladoc Health's average media sentiment score of 0.18 beat Veradigm's score of 0.00 indicating that Teladoc Health is being referred to more favorably in the media.

Company	Overall Sentiment
Teladoc Health	Neutral
Veradigm	Neutral

Veradigm has lower revenue, but higher earnings than Teladoc Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$2.53B	0.48	-$200.32M	-$0.99	N/A
Veradigm	$1.53B	0.38	N/A	N/A	N/A

Veradigm has a net margin of 0.00% compared to Teladoc Health's net margin of -7.13%. Veradigm's return on equity of 0.00% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-7.13%	-12.02%	-5.79%
Veradigm	N/A	N/A	N/A

Teladoc Health has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

76.8% of Teladoc Health shares are held by institutional investors. 0.7% of Teladoc Health shares are held by company insiders. Comparatively, 2.3% of Veradigm shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Teladoc Health presently has a consensus price target of $7.50, indicating a potential upside of 11.74%. Given Teladoc Health's stronger consensus rating and higher possible upside, research analysts plainly believe Teladoc Health is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Teladoc Health beats Veradigm on 9 of the 14 factors compared between the two stocks.

How does Veradigm compare to Schrodinger?

Veradigm (NASDAQ:MDRX) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Veradigm has higher revenue and earnings than Schrodinger.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.38	N/A	N/A	N/A
Schrodinger	$255.87M	4.37	-$103.26M	-$1.41	N/A

79.1% of Schrodinger shares are owned by institutional investors. 2.3% of Veradigm shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Schrodinger had 6 more articles in the media than Veradigm. MarketBeat recorded 6 mentions for Schrodinger and 0 mentions for Veradigm. Schrodinger's average media sentiment score of 0.75 beat Veradigm's score of 0.00 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Neutral
Schrodinger	Positive

Schrodinger has a consensus target price of $20.25, suggesting a potential upside of 33.75%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts plainly believe Schrodinger is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Veradigm has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Veradigm's return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Schrodinger	-40.61%	-30.85%	-15.32%

Veradigm has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

Summary

Schrodinger beats Veradigm on 9 of the 14 factors compared between the two stocks.

How does Veradigm compare to GoodRx?

GoodRx (NASDAQ:GDRX) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

63.8% of GoodRx shares are held by institutional investors. 5.9% of GoodRx shares are held by insiders. Comparatively, 2.3% of Veradigm shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, GoodRx had 1 more articles in the media than Veradigm. MarketBeat recorded 1 mentions for GoodRx and 0 mentions for Veradigm. GoodRx's average media sentiment score of 0.00 equaled Veradigm'saverage media sentiment score.

Company	Overall Sentiment
GoodRx	Neutral
Veradigm	Neutral

GoodRx presently has a consensus price target of $3.81, suggesting a potential upside of 24.19%. Given GoodRx's stronger consensus rating and higher probable upside, research analysts clearly believe GoodRx is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GoodRx has a net margin of 2.61% compared to Veradigm's net margin of 0.00%. GoodRx's return on equity of 7.90% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.61%	7.90%	3.23%
Veradigm	N/A	N/A	N/A

GoodRx has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

GoodRx has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.32	$30.44M	$0.06	51.17
Veradigm	$1.53B	0.38	N/A	N/A	N/A

Summary

GoodRx beats Veradigm on 12 of the 13 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDRX vs. The Competition

Export

Metric	Veradigm	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$611.50M	$1.37B	$7.16B	$12.47B
Dividend Yield	N/A	4.75%	2.59%	9.45%
P/E Ratio	23.25	274.99	282.25	24.66
Price / Sales	0.38	61.50	583.25	89.32
Price / Cash	N/A	30.56	71.23	59.99
Price / Book	N/A	4.61	11.09	5.90
Net Income	N/A	-$25.90M	$3.50B	$336.31M
7 Day Performance	-6.61%	0.35%	-0.24%	0.09%
1 Month Performance	-5.79%	-4.69%	-3.70%	-5.17%
1 Year Performance	-1.03%	-19.71%	61.98%	18.61%

Veradigm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDRX Veradigm	N/A	$4.80 -4.0%	N/A	-1.0%	$611.50M	$1.53B	23.25	8,000	Gap Down
HTFL Heartflow	3.2286 of 5 stars	$25.46 -1.4%	$36.57 +43.6%	N/A	$2.19B	$176.03M	N/A	699	News Coverage Analyst Upgrade Gap Up
CERT Certara	1.8838 of 5 stars	$7.92 +1.7%	$8.85 +11.8%	-15.1%	$1.23B	$419.75M	N/A	1,576	Upcoming Earnings
TDOC Teladoc Health	1.9776 of 5 stars	$6.80 +3.3%	$7.50 +10.4%	-3.3%	$1.22B	$2.49B	N/A	5,600	Trending News Earnings Report Analyst Forecast Options Volume
SDGR Schrodinger	2.3815 of 5 stars	$14.90 -2.9%	$20.25 +35.9%	-22.5%	$1.10B	$254.91M	N/A	790	News Coverage Positive News Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDRX) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradigm (MDRX) Competitors